Proteomic Characterization of Preclinical Neurodegenerative Models with the NULISA™ Multiplex Murine Neuroinflammation Panel 2206

Abstract Description Preclinical models of Alzheimer’s Disease (AD) have been valuable in deciphering the dynamics of disease pathogenesis and evaluating therapeutic strategies. However, the degree to which these models reflect the biology of the disease in humans is not known. With a growing number of preclinical models, deeper proteomic characterization can help to evaluate the differences between these model systems and their clinical utility. To this end, we have developed a 120-plex Murine Neuroinflammation Panel for detection of key neurodegenerative targets, inflammatory cytokines and growth factors. The panel was optimized and validated for murine plasma, CSF and brain lysates. Dilutional linearity, assay reproducibility and detectability were assessed at different sample input volumes. Overall, our studies show robust assay performance with <10% median intra-assay CV and <15% median inter-assay CV. Additionally, detectability in plasma is > 95%, reflecting the high sensitivity of the NULISA™ technology with background suppression mechanisms to achieve detection of a wide dynamic range of proteins. Furthermore, dilutional linearity studies showed good linearity with signal-to-noise ratio >2 for majority of the targets in the panel. Application of this panel in murine models of AD, traumatic brain injury and common strains used for preclinical research show the broad utility of the multiplex NULISAseq Murine Panel for analyzing mechanisms of neuroinflammation and disease pathology in mice. Topic Categories Neuroimmunology (NEUR)